A Phase 1 Study of JADE101 in Healthy Participants
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JADE101 Administered Subcutaneously in Healthy Volunteers
This is a Phase 1, first-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE101 compared to placebo in healthy participants.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a single center, Phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JADE101 in healthy participants. The study will enroll approximately 32 healthy volunteers. JADE101 will be administered by a subcutaneous injection. The results of this study will help inform the dosing and frequency of dosing in future studies of JADE101.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Auckland, New Zealand
- NZCR
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or female participants 18-55 years of age, inclusive
- A body weight between 50-100 kg and a body mass index (BMI) between 18.0 - 32.0 kg/m2 (all inclusive) at screening
- Willing and able to comply with the study site stay, scheduled visits, and study procedures
- Willing and able to comply with using two methods of contraception (one being highly effective) and lifestyle requirements from admission through the end of the study
Exclusion Criteria:
- Harmful alcohol use
- Smoking/vaping or heavy tobacco use within 2 years prior to screening
- Known history of abuse of illicit drugs
- Nursing, lactating or pregnant, or who have plans to become pregnant during the study
- Known history of clinically significant disease
- Known history of immunodeficiency disorder
- History of clinically significant allergic reactions or hypersensitivity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: JADE101
Subcutaneous (SC) injection of JADE101 |
JADE101 is supplied as sterile solution to be administered by SC injection. |
|
Placebo Comparator: Placebo
Subcutaneous (SC) injection of placebo |
Placebo solution to be administered at a matching volume by SC injection. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and Tolerability of Single Ascending Doses of JADE101 in Healthy Participants
Time Frame: Day 1 through 48 weeks
|
Incidence of treatment-emergent adverse events |
Day 1 through 48 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax
Time Frame: Day 1 through 48 weeks
|
Maximum observed serum concentration |
Day 1 through 48 weeks
|
|
Tmax
Time Frame: Day 1 through 48 weeks
|
Time to reach Cmax |
Day 1 through 48 weeks
|
|
AUClast
Time Frame: Day 1 through 48 weeks
|
The area under the concentration-time curve from time zero to the time of the last observed quantifiable (non-zero) concentration |
Day 1 through 48 weeks
|
|
T1/2
Time Frame: Day 1 through 48 weeks
|
Apparent first-order terminal elimination half-life |
Day 1 through 48 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Li Li, MD, Jade Biosciences, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- JADE101-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.